Pharma Major Lupin announced today that it has received final approval for its Tobramycin Inhalation Solution USP, 300 mg/5 ml from the United States Food and Drug Administration (FDA) to market a generic version of Novartis Pharmaceuticals Corporation's TOBI 300 mg/5 ml.